Tango Therapeutics, Inc.
NASDAQ:TNGX
3.1 (USD) • At close December 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Tango Therapeutics, Inc. |
Symbool | TNGX |
Munteenheid | USD |
Prijs | 3.1 |
Beurswaarde | 332,995,800 |
Dividendpercentage | 0% |
52-weken bereik | 2.7 - 13.005 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Barbara L. Weber M.D. |
Website | https://www.tangotx.com |
An error occurred while fetching data.
Over Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)